Furthermore, the methylation status of the IGFBP3 gene was the only statistically significant risk factor for stage II CRC, after adjustment for other prognostic factors such as age, adjuvant 5-FU (5-Fluorouracil) chemotherapy or MSI status (HR = 0.28, 95% CI: 0.12–0.70, p = 0.006; Table 3). This evidence concerns the gene IGFBP3 and colorectal carcinoma.